Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.50−1.16 (-6.22%)
Close on Nov 12, 2026Market cap $127.13MP/E –Yield –
Cue Biopharma operating margin
Operating margin is operating income as a percentage of revenue.
Cue Biopharma's operating margin for the twelve months ending Jun 30, 2026 was -262.0%. For fiscal 2025 it was -96.7%, against -446.9% the year before. The highest annual figure on record is -96.7% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -96.7% | +350.2 |
| FY2024 | Dec 31, 2024 | -446.9% | +503.0 |
| FY2023 | Dec 31, 2023 | -949.9% | +3325.2 |
| FY2022 | Dec 31, 2022 | -4275.1% | −3982.5 |
| FY2021 | Dec 31, 2021 | -292.6% | +1135.4 |
| FY2020 | Dec 31, 2020 | -1428.0% | −364.8 |
| FY2019 | Dec 31, 2019 | -1063.2% | +2323.5 |
| FY2018 | Dec 31, 2018 | -3386.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1113.3% | −821.0 |
| Q1 FY2026 | Mar 31, 2026 | -94.1% | +2827.2 |
| Q4 FY2025 | Dec 31, 2025 | 9.0% | +620.2 |
| Q3 FY2025 | Sep 30, 2025 | -353.4% | −89.2 |
| Q2 FY2025 | Jun 30, 2025 | -292.3% | +98.3 |
| Q1 FY2025 | Mar 31, 2025 | -2921.4% | −2183.6 |
| Q4 FY2024 | Dec 31, 2024 | -611.2% | +148.4 |
| Q3 FY2024 | Sep 30, 2024 | -264.2% | +279.5 |
| Q2 FY2024 | Jun 30, 2024 | -390.6% | +587.4 |
| Q1 FY2024 | Mar 31, 2024 | -737.8% | +6417.3 |
| Q4 FY2023 | Dec 31, 2023 | -759.6% | +9085.5 |
| Q3 FY2023 | Sep 30, 2023 | -543.8% | +15678.3 |
| Q2 FY2023 | Jun 30, 2023 | -978.1% | +49368.1 |
| Q1 FY2023 | Mar 31, 2023 | -7155.1% | −5731.3 |
| Q4 FY2022 | Dec 31, 2022 | -9845.0% | −9749.4 |
| Q3 FY2022 | Sep 30, 2022 | -16222.1% | −15678.5 |
| Q2 FY2022 | Jun 30, 2022 | -50346.2% | −49970.0 |
| Q1 FY2022 | Mar 31, 2022 | -1423.8% | −617.7 |
| Q4 FY2021 | Dec 31, 2021 | -95.6% | +2213.2 |
| Q3 FY2021 | Sep 30, 2021 | -543.5% | +895.5 |
| Q2 FY2021 | Jun 30, 2021 | -376.2% | +641.7 |
| Q1 FY2021 | Mar 31, 2021 | -806.1% | +637.8 |
| Q4 FY2020 | Dec 31, 2020 | -2308.9% | −1449.7 |
| Q3 FY2020 | Sep 30, 2020 | -1439.1% | −718.1 |
| Q2 FY2020 | Jun 30, 2020 | -1017.9% | −142.9 |
| Q1 FY2020 | Mar 31, 2020 | -1443.9% | +1644.5 |
| Q4 FY2019 | Dec 31, 2019 | -859.1% | +2458.0 |
| Q3 FY2019 | Sep 30, 2019 | -720.9% | +2120.7 |
| Q2 FY2019 | Jun 30, 2019 | -875.0% | +3469.2 |
| Q1 FY2019 | Mar 31, 2019 | -3088.4% | – |
| Q4 FY2018 | Dec 31, 2018 | -3317.2% | – |
| Q3 FY2018 | Sep 30, 2018 | -2841.6% | – |
| Q2 FY2018 | Jun 30, 2018 | -4344.2% | – |
See a number that looks wrong?